FUELING INNOVATION: THE ROLE OF SMALL BUSINESSES IN AMERICA'S BIOECONOMY

Senate Small Business Committee Senate April 7, 2026

Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.

[Senate Hearing 119-354]
[From the U.S. Government Publishing Office]

 S. Hrg. 119-354

 FUELING INNOVATION: THE ROLE OF SMALL 
 BUSINESSES IN AMERICA'S BIOECONOMY
=======================================================================

 FIELD HEARING

 BEFORE THE

 COMMITTEE ON SMALL BUSINESS
 AND ENTREPRENEURSHIP

 OF THE

 UNITED STATES SENATE

 ONE HUNDRED NINETEENTH CONGRESS

 SECOND SESSION

 __________

 APRIL 7, 2026

 __________

 Printed for the use of the Committee on Small Business and 
 Entrepreneurship
 
[GRAPHIC NOT AVAILABLE IN TIFF FORMAT] 

 Available via the World Wide Web: http://www.govinfo.gov
 
 __________
 
 U.S. GOVERNMENT PUBLISHING OFFICE
63-367 WASHINGTON : 2026
=======================================================================
 
 COMMITTEE ON SMALL BUSINESS AND ENTREPRENEURSHIP
 ONE HUNDRED NINETEENTH CONGRESS

 ---------- 

 JONI ERNST, Iowa, Chair
 EDWARD J. MARKEY, Massachusetts, Ranking Member
JAMES E. RISCH, Idaho MARIA CANTWELL, Washington
RAND PAUL, Kentucky JEANNE SHAHEEN, New Hampshire
TIM SCOTT, South Carolina COREY A. BOOKER, New Jersey
JOSH HAWLEY, Missouri CHRISTOPHER A. COONS, Delaware
TED BUDD, North Carolina MAZIE K. HIRONO, Hawaii
JOHN R. CURTIS, Utah JACKY ROSEN, Nevada
JAMES C. JUSTICE, West Virginia JOHN W. HICKENLOOPER, Colorado
JON HUSTED, Ohio ADAM B. SCHIFF, California

 Meredith West, Republican Staff Director
 Sean Moore, Democratic Staff Director
 
 C O N T E N T S

 ---------- 

 APRIL 7, 2026
 Opening Statements

 Page
Todd Young, U.S. Senator from Indiana............................ 1

 Witnesses
 Panel 1

Alina Alexeenko-Peroulis, Ph.D., Co-Founder and President, 
 LyoWave, Inc., West Lafayette, Indiana......................... 2
 Prepared Statement........................................... 5
Mr. Aaron Schacht, CEO and Board Director, BiomEdit, Inc., 
 Greenfield, Indiana............................................ 8
 Prepared Statement........................................... 10
Mr. Derek Andrew Small, Co-Founder, Chairman and CEO, Monument 
 Biosciences, Inc., Indianapolis, Indiana....................... 17
 Prepared Statement........................................... 20
Mr. Mark Warner, Co-Founder and Chief Technology Officer, 
 Liberation Bioindustries, Richmond, Indiana.................... 22
 Prepared Statement........................................... 24

 Panel 2

Mr. David Rosenberg, President and CEO, Indiana University Launch 
 Accelerator for Biosciences (IU LAB), Indianapolis, Indiana.... 35
 Prepared Statement........................................... 38
Mr. Vincent J. Wong, CEO and President, BioCrossroads and 
 Crossroads Health Ventures, Indianapolis, Indiana.............. 46
 Prepared Statement........................................... 48
Ms. Michelle Dennis, Regional Innovation Officer, Heartland 
 BioWorks Tech Hub, Indianapolis, Indiana....................... 54
 Prepared Statement........................................... 56

 
 FUELING INNOVATION: THE ROLE OF SMALL BUSINESSES IN AMERICA'S 
 BIOECONOMY

 ---------- 

 TUESDAY, APRIL 7, 2026

 United States Senate,
 Committee on Small Business
 and Entrepreneurship,
 Washington, DC.
 The committee met, pursuant to notice, at 10:28 a.m., at 
Carmel City Hall, 2nd Floor, 1 Civic Square, Carmel, Indiana, 
Hon. Todd Young, presiding.
 Present: Senator Young [presiding].

 OPENING STATEMENT OF SENATOR YOUNG

 Senator Young. The perfect setting to host a hearing on the 
importance of American leadership in biotechnology. Our State 
is at the crossroads of advanced manufacturing, life sciences, 
and agricultural innovation, making it a powerful example of 
how the bioeconomy can thrive when research, industry, and 
workforce development come together. From world class 
institutions, to a highly skilled workforce, a strong network 
of entrepreneurs, and access to private capital, innovators 
across Indiana are driving breakthroughs that not only support 
local economies, but also strengthen our national 
competitiveness.
 As chair of the National Security Commission on Emerging 
Biotechnology, I've seen firsthand how critical biotechnology 
is, not only to our economic growth, but to our national 
security. The ability to innovate and scale biotechnology here 
at home will shape our competitiveness, resilience, and 
security for decades to come. Congress has already taken 
important steps to reinforce this leadership through the CHIPS 
and Science Act, which made historic investments in domestic 
research development and manufacturing.
 While much of that focus has been on semiconductors, the 
law underscores a broader commitment to strengthening America's 
innovation ecosystem, one that must fully include biotechnology 
and the small businesses driving it forward. Today's hearing 
will explore how small businesses power innovation and help 
position the United States as a global leader in biotechnology. 
Small businesses are often the engines of discovery, moving 
quickly, taking risks, and transforming cutting edge research 
into real world applications. They play a critical role in 
translating ideas from the lab to the marketplace, creating 
jobs, and fostering economic growth in communities across the 
country.
 At the same time, these businesses face unique and 
persistent challenges, including limited access to capital, 
complex and sometimes burdensome regulatory frameworks, and 
difficulties in attracting and retaining a highly skilled 
workforce. Addressing these barriers is essential if we want to 
unlock the potential of America's bioeconomy. This hearing will 
examine how partnerships between small businesses, research 
institutions, and government can accelerate innovation and 
ensure that breakthroughs are not only developed but scaled 
here at home. Federal programs must be not only responsive but 
proactive in empowering the next generation of biotech 
entrepreneurs. Strengthening the bioeconomy is not just about 
scientific advancements, but maintaining America's leadership 
on the world stage.
 As global competition intensifies, it's critical that we 
continue to invest in innovators who are driving this sector 
forward. So, I look forward to productive discussions today, 
and to hearing directly from our witnesses about the 
opportunities and challenges they see on the ground. Thank you 
for your time, your expertise, and your commitment to advancing 
American innovation.
 The hearing today will feature two panels: the first 
comprised of industry leaders, followed by a second panel with 
commercialization experts. With that, we'll now proceed to our 
first panel. I want to extend a warm welcome to all of our 
witnesses. I'm thankful that you took time out of your busy 
schedules to participate today, and share your expertise on the 
role of small business in America's biotech ecosystem.
 We'll start with Dr. Alina Alexeenko, co-founder and 
president of LyoWave, and the Rilley Professor of Aeronautics 
and Astronautics and Chemical Engineering at Purdue University. 
LyoWave is an SBIR grantee for innovative microwave heating 
technologies developed at Purdue. Next, we have Aaron Schacht. 
Mr. Schacht is CEO and board director of BiomEdit, an animal 
health company specializing in microbiome innovation. He's also 
a board member of the Purdue Research Foundation, and the 
Indiana Biosciences Research Institute.
 Next, Mr. Derek Small is the co-founder, chairman, and CEO 
of Monument Biosciences. He's also managing director of Luson 
Bioventures, as well as the CEO of Syndeio Biosciences. 
Monument is bringing forward the next generation of Alzheimer's 
drugs. And our last witness on this first panel is Mr. Mark 
Warner. He is co-founder and CTO of Liberation Bioindustries, 
which is building a global network of precision fermentation 
facilities to produce bio-based consumers products at scale.
 So, I ask unanimous consent that the witnesses' full 
statements be included in the record. Without objection, so 
ordered. And as your written testimony has been made part of 
the record, the committee asks that each of you limit your oral 
remarks to 5 minutes.
 With that, Dr. Alexeenko, you're recognized for 5 minutes 
for your testimony.

 STATEMENT OF DR. ALINA ALEXEENKO-PEROULIS CO-FOUNDER AND 
 PRESIDENT, LYOWAVE, INC.; REILLY PROFESSOR, AERONAUTICS AND 
ASTRONAUTICS AND CHEMICAL ENGINEERING, PURDUE UNIVERSITY, WEST 
 LAFAYETTE, INDIANA

 Dr. Alexeenko-Peroulis. Thank you, Senator Young, 
distinguished guests. I really appreciate the opportunity to 
testify today. So, I'm here on behalf of West Lafayette, 
Indiana, startup that's based on innovations developed at 
Purdue University. LyoWave was established--was incorporated in 
2023, to solve one of the major bottlenecks in 
biomanufacturing, and that's lyophilization. Also known as 
freeze drying, it's a process that happens in space, like a 
vacuum. It is, you know, one of the critical processes to 
stabilize complex biological molecules so that they can be 
stored, transported, and delivered to patients safely.
 I know some of the companies--some are with actually using 
this technology, and lyophilization is a workhorse of 
biotechnology. We're not just developing a faster workhorse. We 
are aiming to replace it with an all-terrain vehicle that can 
deliver novel and legacy biotech products to market safely and 
at scale.
 The history of lyophilization underpins the kind of the 
story, the origin of American leadership and biotechnology. It 
actually starts about 85 years ago, in spring 1941, several 
months prior to the United States entry into World War II, U.S. 
Army and Navy launched a massive public private partnership 
effort to supply freeze-dried blood plasma to the battlefields 
in Europe. It was later named one of the foremost lifesavers of 
Allied soldiers in Europe, and one of the key medical armaments 
for Allies' victory.
 And that capacity to freeze-dried blood plasma during World 
War II was actually essential for manufacturing of the first 
antibiotic, penicillin, that saved millions of lives around the 
world. And that fermentation capacity, as well as human 
expertise developed for first antibiotics, has secured 
America's leadership in biotechnology when it emerged in the 
1970s.
 And we are again at an inflection point. There is an 
urgency to innovate. Lyophilization, today, taking this 
manufacturing unit process separation, as an example, is a 
critical step to manufacture recombinant protein drugs that are 
used for, say, heart attacks and autoimmune diseases, targeted 
therapies for cancer vaccines, gene therapies, microbiome 
products, to name a few diagnostic reagents. Majority of 
essential antibiotics on the essential medicines list are 
manufactured in lyophilized form, yet, the process itself 
remains very slow and energy inefficient and one of the most 
expensive steps in biomanufacturing.
 So, in 2015, through Advanced Manufacturing Technology 
Consortia Program, Purdue and partners established LyoHUB, an 
industry-university consortium that developed first technology 
roadmap for lyophilization. And one of those technologies, 
potential innovations that we identified in pursuit with the 
team was to use a disruptive technology based on radio 
frequency semiconductor, use microwave heating to speed up 
lyophilization.
 With early support from the university, through PRF Trust 
Fund and competitively awarded grant from NIIMBL, partnering 
with Merck and IMA Life, we developed a prototype of this 
technology, and were able to test drive it on real biologic 
supplied by Merck. This partnership was transformative. It 
allowed us to move from lab-based invention to company 
creation, and in 2024, LyoWave was able to raise our first 
venture capital round and license, that allowed us to pay for 
the license IP license from Purdue and create our first jobs 
here in Indiana.
 Through SBIR phase 1 grant awarded in 2025, we were able to 
expand the team's expertise, especially in mechanical 
engineering and software engineering, and delivered our first 
microwave TurboDry system to a customer on U.S. East Coast. 
This lab-scale prototype, the first lab-scale prototype, would 
hardly fit in a minivan. Our first product actually can be 
carried--can fit into a carry on, and delivered and installed 
in less than an hour, while increasing manufacturing capacity. 
So, we are now in a steep climb to transition, this innovation, 
into GMP-regulated manufacturing, and there are many other 
possible innovations that can bolster U.S. leadership and 
biomanufacturing.
 Based on this experience, I want to suggest these three 
recommendations. First, continue strengthening existing 
programs like SBIR/STRR and motivate small business 
participation in programs on end-to-end--reshoring of end-to-
end manufacturing to U.S. of critical medicines, and biologics 
such as those by ASPR. Second, provide incentives to help 
offset regulatory costs, incentives to adopt this advanced 
manufacturing technologies. And one specific recent example is 
Advanced Manufacturing Technology Designation Program by FDA, 
which is the first step in the right direction.
 And third, establish a national network of regional, 
shared-use facilities that are available to innovators that 
provide GMP-relevant equipment and environments to test drive 
these new technologies. Those facilities would function as 
pathways for innovation--in American innovation and biotech 
manufacturing. With these partnerships--with the right 
partnerships, policies, and support for growing businesses, I 
believe we can fuel America's bioeconomy for generations to 
come.
 Thank you for the opportunity to testify, and I look 
forward to your questions.
 [The prepared statement of Dr. Alexeenko-Peroulis follows.]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 
 
 Senator Young. Thank you, Doctor. Mr. Schacht, you're 
recognized for 5 minutes for your testimony.

 STATEMENT OF MR. AARON SCHACHT, CEO AND BOARD DIRECTOR, 
 BIOMEDIT, INC., GREENFIELD, INDIANA

 Mr. Schacht. Thank you, Senator Young, for the--and 
distinguished guests for the opportunity to testify today. My 
name is Aaron Schacht. I'm the CEO of BiomEdit. We're a 
biotechnology company based here in Indiana, and we developed 
synthetic biology solutions using engineered microbes to 
address challenges in animal health, animal agriculture, and 
increasingly, areas that we believe are relevant to human 
health. I'd like to focus my remarks on three main points. 
First, the opportunity in animal health. Second, the structural 
friction that limits innovation for small companies in this 
sector. And third, why this matters in the context of national 
interests.
 First, the opportunity. Animal health is often treated as a 
secondary market relative to human biotechnology. It's 
understandable. In practice, it plays much more of a strategic 
role. It sits at the intersection of food security, public 
health, environmental sustainability, and biological 
innovation. At BiomEdit, we're developing a product to address 
an infectious disease in poultry, using an engineered microbe 
that delivers targeted proteins to the gastrointestinal tract, 
thereby protecting these birds from this disease in a non-
antibiotic platform.
 But the important point is not the individual product, it's 
the platform and the approach. Small companies and animal 
health are working to test new and novel biological delivery 
systems. We're validating these mechanisms and technologies in 
real world environments, and we're generating data at very 
meaningful scale.
 In doing so, we often represent the opportunity to de-risk 
technologies that can later be applied in human health, and we 
do so at a quicker pace and a lower cost. This creates a 
natural bridge between agricultural innovation and biomedical 
innovation, one that is currently, I believe, underleveraged.
 Second, the friction. Despite this opportunity, animal 
health innovation is structurally undercapitalized. Compared to 
human biotechnology, capital is more limited, investor 
familiarity is lower, and pathways to scale are, well, less 
pioneered and defined. The result is straightforward: fewer 
entrepreneurs build in this space, fewer ideas as a result are 
pursued, and technologies are often pushed prematurely into 
human applications.
 This is not a science problem. It's an ecosystem problem. 
Small companies are doing this work with constrained capital, 
limited infrastructure, and pathways that are not always 
optimized for novel approaches. The consequence is not simply 
slower progress. It's missed innovation.
 Third, why this matters. The U.S. protein supply is a 
fundamental, foundational component of national stability. It 
is exposed to disease threats like avian influenza and African 
swine fever, and potentially deliberate disruption through 
biological means from malicious actors. Animals also serve as 
sentinel species in zoonotic reservoirs, meaning challenges in 
animal health can quickly become challenges or solutions in 
human health. In this context, innovation in animal health is 
directly tied to the resilience of our food system, continuity 
of supply of food and national preparedness as it relates to 
infectious disease. Small biotechnology companies are often 
where the most novel solutions originate and progress most 
rapidly. The question is not whether innovation will occur, it 
is whether it will occur fast enough at appropriate scale and 
within the United States.
 Finally, one additional perspective on the role of animals 
in research. Historically, animals have primarily served as 
models for human biology. We now have the opportunity to evolve 
this model by investing directly in animal health innovation. 
We can develop therapies that benefit animals, improve animal 
welfare, and generate insights that translate into human 
medicine. In that sense, animals are not only participants in 
research, but they can also be recipients of its benefits.
 In closing, the bioeconomy is being built today, often by 
small companies operating at the edge of what is technically 
possible. Animal health is a critical but underrecognized part 
of that system. With the right attention, it can strengthen our 
food supply, improve resilience, and accelerate progress across 
both animal and human health.
 Thank you, and I look forward to your questions.
 [The prepared statement of Mr. Schacht follows.]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Senator Young. Thank you, Mr. Schacht. Mr. Small, you're 
recognized for 5 minutes for your testimony.

 STATEMENT OF MR. DEREK SMALL, CO-FOUNDER, CHAIRMAN AND CEO, 
 MONUMENT BIOSCIENCES, INC., INDIANAPOLIS, INDIANA

 Mr. Small. Thanks for having me here today, Senator Young, 
and the opportunity to testify.
 So, in your opening, you introduced us all, and I love 
hearing these stories, by the way, that's really part of 
entrepreneurship, and the spirit of this is innovation, and the 
challenges that we all go through. I've been doing this now for 
over 25 years, starting new companies, not always in 
biotechnology, but since 2002, or so, in biotech. 10 different 
companies, have more than 10 actually, several different 
products we've developed along the way, too. So, really, quite 
a bit of trial and error, different ideas that we advance from 
science into, hopefully, commercialized situations.
 As you mentioned earlier, I'm currently the CEO of a 
company called Monument Biosciences. We are based here in 
Indianapolis focused on Alzheimer's disease as a therapeutic 
category, but really trying to harness innovation that happens 
at the academic setting in university. Right now, the majority 
of our technology comes from Indiana University School of 
Medicine. Another group that Aaron is a part of called the 
Indiana Biosciences Research Institute and Purdue.
 So, really, we're pulling a lot of technology from these 
specific universities. I've actually partnered with several, 
you know, universities for these companies from all over the 
world, really the coast, the larger schools, but really the 
ecosystem here in Indianapolis has been extraordinary for 
starting this company. I launched these out of my firm called 
Luson Bioventures, which is really dedicated to starting new 
biotech companies, kind of a venture creation as much as a 
venture capital company. Also, as part of that process of 
launching a company also in brain health called Syndeio 
Biosciences, and that's all been a focus that I shifted over 
into neuroscience in 2017.
 As I mentioned, 2002, kind of starting my life into 
biotech, but 2017, a lot of things changed for me. I got to 
experience a lot of success, I guess, across companies in 
science and clinical development. But I also spent 2 years 
being primary care provider for my father who died in 2017 of a 
dementia-related--early onset dementia. And that fueled, you 
know, a thought process for me, changed how I think about 
venture creation and entrepreneurship to something that's a 
little more personal, certainly very science rooted. And we 
have business fundamentals, and we have shareholders and people 
we are accountable to, but focusing on Alzheimer's became an 
important concept for me.
 And so, I think, for us here today, biotech, as you 
mentioned, I think actually really well up front. It's not an 
ordinary small business situation. It's a different type of 
ecosystem. It's mostly research and development. It's a lot of 
innovation. I think there's some really cool stats here, too, 
that over 80 percent of the transformative medicines approved 
by FDA through our history of the pharmaceutical industry have 
come from early stage, you know, startup company, innovative 
team situations, not necessarily the Big Pharma companies that 
most people think of too. So, I think this is an 
extraordinarily important subject.
 One of my companies was called Naurex, it was acquired for 
a decent amount of capital. So, there's a lot of success that 
can happen here if we're mindful of innovation and what it 
takes to kind of achieve success in these innovative companies. 
That company started from an SBIR grant that we were awarded, 
and then, probably, 10 more grants that we ended up having, to 
really focus on and kind of get more access to before we were 
able to attract the first venture capital dollars, and, 
ultimately, almost take that company public before it was 
acquired.
 Started another company called Assembly Biosciences, which 
ultimately we were able to take public and is listed on Nasdaq 
today, too, but also entirely initially based on NIH grants and 
then SBIR grants and then other grants that we were able to 
receive to be able to advance those projects and technologies 
because there's always something, whether it's lyophilized 
product that we have to pay for, like a microbiome technology, 
which I've developed in companies, too. I mean, these are 
things that we just all need as companies that aim to maintain 
our innovation and kind of fill the supply chain.
 So, these companies, Monuments and Syndeio, they're the 
same kind of investments as those first two companies are at an 
earlier stage now, too, but also, actually, in a little bit 
more advanced medical environment. We've had some approvals 
recently for Alzheimer's drugs that give us hope that we can be 
successful in what we're doing. They're not the most 
successfully advanced drugs for patient benefit. They're not 
cures for patients. Right? I mean, initially when they were 
approved, I wasn't even sure I would have been willing to give 
them to my father for his situation. I wasn't quite sure of the 
risk/benefit. I'm more encouraged by that now, too, but it 
really is just about innovation. It's about being able to bring 
forward the next therapies that we can develop.
 And so, I've tried to be very specific to about three 
things that I think that I would be interested in getting 
national help for. I think that they're very actionable for 
developing novel drugs and innovation. First is, you know, 
specifically, the NIH funding. I think, and I'm learning more 
about kind of different perceptions at the national level for 
NIH activities and funding, but I do think it's absolutely 
critical. I think it sometimes gets characterized as a cost 
center, but it's a major investment with a huge return to 
society and to the field, not necessarily just to 
entrepreneurial companies. It's, you know, a major producer of 
jobs and employment, of course, too. And, you know, it's 
something that I think our competitors globally, including 
China, have invested in significantly in a way that I think we 
have to be mindful of from our standpoint.
 Second is the specific SBIR and STRR. For biotech, it's a 
little more expensive to get to these early-stage proof of 
concepts, especially than it was a few years ago. So, I think 
there are some, you know, parameters of those. We work really 
hard to usually get our first three, to five, or more 
applications turned down, or they don't meet certain criteria. 
You keep rewriting them, and you have to bring them forward and 
resubmit and so on. It's a process for all of us that have 
written grants.
 But then getting them, I think, the criteria for biotech, 
is a little more expensive. So, there are ceilings associated 
with phase 1 and phase 2. I do think raising those ceilings 
would be meaningful, from a $300,000 limit to closer to $1 
million to $3 million limit.
 And third is a little more business-oriented, and it's 
aligning incentives, as was brought up a little bit earlier, 
too. There's a specific tax incentive called the QSBS, 
Qualified Small Business Stock tax incentive, that I've asked 
my science founders and our investors have benefited from in 
our companies. And that absolutely works as a flywheel for the 
next investments for the ability to encourage additional 
investments in the private sector. It was a really kind of 
simple code change and opportunity for change at a national 
level.
 So, I do think we have at Indiana a really unique position 
at both entrepreneurial. So, I'm really glad you're having this 
here, too. I think we are kind of a diamond in the rough. And 
it's rare that we really kind of toot our own horn about that. 
But specifically in Alzheimer's disease research, we have a 
unique competitive advantage at the academic level.
 We have the most successful pharmaceutical company is also 
getting drugs approved in Alzheimer's disease, too, with Eli 
Lilly and ecosystem for companies that we have sitting at this 
table, but also several more down that you might hear some from 
in the next panel too, from that are supported by BioCrossroads 
or IU LAB. So, really a unique opportunity that I do think that 
a national agenda will make some significant progress for us 
here right in the State.
 Thank you for your time.
 [The prepared statement of Mr. Small follows.]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Senator Young. Thank you, Mr. Small. Mr. Warner, you're 
recognized for 5 minutes for your testimony.

STATEMENT OF MR. MARK E. WARNER, CO-FOUNDER AND CTO, LIBERATION 
 BIOINDUSTRIES, RICHMOND, INDIANA

 Mr. Warner. Thank you. Senator Young, and distinguished 
guests, my name is Mark Warner. I am co-founder and CTO of 
Liberation Bioindustries, a company working to bring fit for 
purpose biomanufacturing to the U.S., with our first facility 
under construction in Richmond.
 The United States leads the world in biotechnology 
innovation, but consistently fails to translate that leadership 
into domestic manufacturing. Nowhere is this more evident than 
in industrial biotechnology, where breakthrough processes are 
developed domestically, but commercialized elsewhere. It is 
quite simply become a system driving small business value 
creation outside of the U.S.
 My testimony argues that the Small Business Administration 
is uniquely positioned to address this gap. Industrial 
biotechnology is overwhelmingly driven by small businesses, 
yet, commercialization requires capital intensive 
infrastructure that falls outside the traditional SBA support 
framework, where currently there is no bankable support, public 
or private, for first-of-a-kind facilities. By adapting its 
programs to support first-of-a-kind manufacturing in 
biotechnology, the SBA can play a decisive role in converting 
innovation into operating assets, strengthening U.S. 
competitiveness and industrial resilience.
 Industrial biotechnology is often perceived as a large-
scale industry, but its innovation base is overwhelmingly 
composed of small businesses. The companies developing 
fermentation processes, synthetic biology platforms, and bio-
based production pathways typically have fewer than 1 to 200 
employees, and are pre-profit and capital constrained. They are 
small businesses attempting to build entirely new manufacturing 
systems.
 Development pathway is consistent: small companies 
innovate, develop pilot processes, then attempt to build their 
own commercial facility. At that moment, capital requirements 
increase dramatically, but the companies themselves remain 
small. This creates a structural mismatch. Small businesses are 
responsible for building large industrial assets without access 
to financing tools for the transition.
 Primary barrier in industrial biotechnology is not 
scientific. It's commercialization. The U.S. Government support 
reinforces the outcome. We fund innovation that ends up getting 
scaled overseas. Capital requirements scale rapidly from tens 
of millions to hundreds of millions. Companies become too large 
for venture funding, yet, remain too risky for traditional 
project finance. This creates a persistent financing gap at the 
point of greatest leverage.
 Scale currently happens in Europe, China, and Asia, not 
because they're more innovative than the U.S., but because they 
simply fund infrastructure better. This results in U.S. dollars 
going into foreign manufacturing, and when first plants are 
built overseas, we export the learning curve and future 
innovation.
 Industrial biotechnology aligns directly with SBA's core 
mission. The sector is driven by small, innovative, capital-
constrained companies attempting to grow to scale. However, 
unlike traditional small businesses, success requires building 
manufacturing infrastructure rather than an expanding service 
or incremental operation. It's just simply a different support 
model.
 The SBA is uniquely positioned to bridge this gap by 
supporting the transition from technology development to asset 
ownership. This is the precise point when small businesses 
either scale into industrial players or fail to commercialize 
entirely. The three recommendations we can offer are one; to 
expand loan guarantees for first-of-a-kind biotech facilities, 
two, create a biotechnology commercialization track, and three, 
support shared infrastructure.
 In conclusion, industrial biotechnology represents a 
critical opportunity for the United States, but only if the 
innovation translates into domestic manufacturing. The 
companies driving this transformation are small businesses. The 
infrastructure they require is not. Bridging the gap is where 
the SBA can have an outsized impact. If the United States is 
serious about maintaining leadership in biotechnology, it must 
support not just the invention, but the ability to build. The 
SBA can and should be a central part of this solution.
 Thank you.
 [The prepared statement of Mr. Warner follows.]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Senator Young. Well, thank you, Mark, and thanks to all of 
our witnesses for not only your thoughtful testimony, but for 
your recommendations. You'll be encouraged to know before I 
proceed to questions, I'd like to emphasize that the National 
Security Commission on Emerging Biotechnology spent 2 years 
studying, among other challenges, some of the challenges each 
of you have articulated. A number of the recommendations you 
have put forward have been included, or variants thereof, in 
our recommendations to Congress, but not all of them. So, you 
should be encouraged by that as well. We continue to formulate 
new policy ideas, working with other stakeholders.
 And that's a good launching off point to begin with the 
questions, and I'll begin with you, Dr. Alexeenko. Each of you 
discussed the SBIR and STRR program, and its importance to you, 
including to the LyoWave company that you have co-founded. 
LyoWave received, according to my notes, a phase 1 SBIR grant 
award. And so, I want to know, Doctor, how can Federal programs 
like SBIR and STRR better support early-stage biotech companies 
in overcoming the Valley of Death that's often characterized as 
one of the biggest barriers to commercialization in this 
industry. I think I've heard greater resourcing to recipients 
is important in certain instances, maybe a tiered--adopting a 
tiered structure, as Mr. Small indicated. So, treating biotech 
differently, knowing that it takes, oftentimes, more resources 
to ultimately commercialize products. So, I'll just leave it to 
you, and you can run wherever you like to with this question, 
Doctor.
 Dr. Alexeenko-Peroulis. Yeah. Thank you so much, Senator 
Young. This is a great question, and something we've been 
thinking and living for the past year. Our SBIR phase 1 awards 
started March 1, 2025, and we just submitted our final report 
for this 12-month, phase 1, and I've been thinking what--with 
our team. So, what it allowed us to do, it allowed us to bring 
our first product to customer much, much faster. We were able 
to hire our first non-founder employee--Steven, actually, he's 
here--retain great talent to Indiana. And we were able to, for 
example, pay for the software licenses, and speed up the design 
of our systems and build it much faster.
 I also want to say that, here in Indiana, we have the best 
deal on SBIR. Seriously, one of the best deals, because, I 
think, through IDC, Applied Research Institute handles actually 
cost share the SBIR, and they awarded us an additional $50,000 
that allowed us to do, for example, to pay for some of the 
equipment that's otherwise not allowed on those grants so that 
we can buy instrumentation to develop our hardware faster.
 Senator Young. Can I interject, Doctor? So, with that 
additional $50,000, would that accrue to the company and pay 
for investments, or is that part of the application process----
 Dr. Alexeenko-Peroulis. Yeah, that----
 Senator Young [continuing]. And therefore, it receives more 
favorable weighting because it would be $50,000 less of Federal 
dollars that would have to go to a worthy recipient.
 Dr. Alexeenko-Peroulis. In the time that we submitted the 
application----
 Senator Young. Yes.
 Dr. Alexeenko-Peroulis [continuing]. That was not part of 
the application.
 Senator Young. I see.
 Dr. Alexeenko-Peroulis. This was a great addition. After we 
got awarded----
 Senator Young. Supplementary. Okay.
 Dr. Alexeenko-Peroulis [continuing]. We became eligible for 
the supplement. You know, meeting some of the other 
requirements for being an innovative business based in Indiana, 
and actually making a commitment to stay in Indiana and grow in 
Indiana. So, that was an additional $50,000 that allows more 
freedom, actually, of how to spend these resources to develop 
products and to perform research. And so, that was very 
important.
 I also want to mention some of the venture capital 
investment incentives that exist only in Indiana, and that's an 
addition to what was mentioned before by Mr. Small. There is a 
VC incentive in Indiana that allows, actually, investors get 
the best deal by investing in companies in Indiana.
 Senator Young. So, Mr. Small, because your reference, 
because you had some thoughtful suggestions as it relates to 
this topic. I'm going to pivot to you and see if you have any 
additions to make in terms of thoughts about how we could 
optimize the SBIR/STRR program. But also, you had--you've 
offered a recommendation related to the qualified small 
business tax incentives that I've never received before in the 
couple of years of working on this. So, if you could unpack 
that a little bit more and explain how that works from an 
investor standpoint.
 Mr. Small. Yeah. Well, I would have to have my CFO come up 
and give all the specific details of what happens.
 Senator Young. But for a layperson.
 Mr. Small. Yeah, for me, it was an interesting incentive, I 
thought, actually, and I didn't know about it until my 
financial advisor figured it out and kind of told our whole 
community about this. And now, we've figured this out. So, 
essentially, it's a holding period associated with founders' 
shares of stock so early or early investors, so people who hold 
common shares or make equity investments in companies, and they 
hold that for at least 5 years. And then after 5 years, that's 
treated with a tax incentive. I forget the full incentive, but 
it's a significant up to $10 million investment, but it's also 
like a percentage that you do not pay ordinary income tax 
associated with that. So, it ends up savings for large 
transactions. It saves several million dollars, and that goes 
to those investors, and it can apply to investors as well as 
the founders or science founders, too, for these companies, 
which in biotech, again, for everything we talked about how 
much more capital is required.
 I think those supplemental grants that Dr. Alexeenko is 
mentioning are really in that same kind of concept, it is more 
expensive. And so, there's like finding ways to make 
supplements and what have you too, but specifically, this tax 
incentive allowed all the investors to do better for 
companies----
 Senator Young. Yes.
 Mr. Small [continuing]. As part of their early investment 
and their willingness to hold longer because biotech takes 
longer. And then that has allowed us then they make a little 
bit more money, and then, we rinse and repeat. We start another 
company. They have more investors.
 Senator Young. So, we're going to chase this down and we'll 
let you know what direction we go with it and why. Mr. Schacht, 
I'm so glad you're here because you bring a unique perspective 
to this conversation with the animal health focus. You 
mentioned in your testimony that the animal health innovation 
market differs structurally from human biotech. Can you 
elaborate on how advances in animal health can translate into 
insights for human medicine and strengthen the broader 
scientific ecosystem? If you have any compelling examples, we 
welcome them.
 Mr. Schacht. Great, great question. In fact, many--as you 
know, in human biomedical research, animals are often used as 
testing systems to evaluate whether or not something is safe or 
whether something is efficacious, and in many cases, what we do 
on the human side. I spent the first 25 years of my career at 
Lilly in human pharma, is we create sort of artificial versions 
of a disease that afflicts humans in an animal, it's called an 
animal model, and we test our drugs early to give us confidence 
that the biological approach we're taking is mechanistically 
relevant to treating disease. And the sad part about this is 
these are purpose-bred animals. So, that's good. They're 
purpose-bred for this purpose. But at the same time, all of the 
insights that get generated really accrue to human biomedical 
innovation and no benefit befalls those dogs or cats that might 
actually be part of that process.
 So, an example I could provide, very specifically, that is 
a BiomEdit focus is we engineer bacteria to deliver 
biomolecules to the gut. And our lead product is focused on 
broiler chickens and knocking down the disease burden caused by 
an infectious pathogen that produces toxins in the gut of the 
chicken that make the chicken sick. The name of that pathogen 
is Clostridium perfringens. There's another Clostridium species 
that affects humans called Clostridium difficile. And if you 
know anything about this, this is a disease that often plagues 
mature adults, and causes really serious disease in the gut.
 The mechanism that we've pioneered at BiomEdit for chickens 
could be leveraged identically in humans for the same approach. 
Our product will be approved by the USDA later this year, and 
it's the first product of its kind. We've created a path for an 
engineered biological therapeutic to be approved by a 
regulatory agency in a species in any geography, and that will 
be the first time that has occurred. But it opens the door for 
people looking at the application in humans as less risky now, 
because we've proven it in animals.
 Senator Young. It's very helpful. And I would say this is, 
among the topics, businesses like yours are among those that we 
consulted with as we formulated our various recommendations. 
One of the primary recommendations, in fact, that the 
Commission developed was to put someone in charge within the 
White House from a regulatory standpoint so we can see across 
different agencies and serve as a sort of traffic cop. It's not 
uncommon for entrepreneurs, investors to have to deal with 
three different regulatory agencies when they're getting off 
the ground, slowing things down; FDA, USDA, EPA, and that 
significantly leads to all sorts of confusion and delay, and 
therefore causes our investors to burn capital. So, that rhymes 
with some of your insights.
 Mr. Small, given your experience launching several 
companies, which you mentioned, what do you see as the most 
critical factor if you had to distill it down in helping early-
stage discoveries successfully develop ultimately into 
marketable products?
 Mr. Small. Yeah. I think it's been said a couple of times 
that it's probably not scientific. It's financial, it's 
business, and I think a lot of these things have incentive 
alignment and kind of bridging the gap, or this Valley of 
Death-type of thing, I think, is a common theme that I think is 
not as huge of a chasm as I think people think it is.
 I think there are small investments at early stages and 
risk taking to cross a certain threshold that become like an 
activation energy threshold that we always seem to be just 
below. But the expectation is that, well, we can't, that's not 
something we can address necessarily. So, I think there is an 
activation energy capital at an early stage that could be 
meaningfully impactful to making all of these companies more 
successful.
 Senator Young. Thank you. Mr. Warner, you were paraphrased 
right there. You indicated the primary barrier for success and 
for small biotech businesses is not science but 
commercialization. With that in mind, in your view, what are 
the biggest financing gaps today, particularly at the first-of-
a-kind facility stage that is so important to your business, 
which I have visited----
 Mr. Warner. Yeah.
 Senator Young [continuing]. Out in the field and seen how 
capital intensive it is, and what specific tools are needed to 
ensure that U.S.-funded innovation is scaled here rather than 
overseas?
 Mr. Warner. Thank you. The main key is really, I would say, 
getting a legislative process that really emphasizes 
manufacturing. We talk about manufacturing, but when we look at 
technologies like chips, solar power, nuclear power, and rare 
earths, all of which were developed here, manufactured 
initially, and have moved overseas because the manufacturing 
moved overseas.
 I literally started 40 years ago with a company called 
Rhone-Poulenc. We were the last rare earth manufacturer in 
Freeport, Texas. The process that's being used in China today 
is the process they had because we didn't want to manufacture 
it anymore. When I see what's happening in biotech, I see that 
happening. Most of the technologies we're competing with are 
from overseas. So, I don't want to get misconstrued. We need 
the development dollars, but as a country, we've gotten in a 
bad habit of when we don't manufacture.
 And the biggest concept is when manufacturing moves 
overseas, technology leadership moves overseas. When I 
graduated in the late 1980s, we had chip expertise. Half of my 
class went to Intel and things. Then in the '90s, they were 
pushed to move to Korea and Japan. So, that's the biggest 
thing. And this is great for Indiana because Indiana gets 
manufacturing. That's why we're here. I guess I would say the 
broader U.S. could learn some from that.
 Senator Young. So, if we stated differently, if we want 
supply chain resiliency, we need to invest in it----
 Mr. Warner. Correct.
 Senator Young [continuing]. And if we want a talented 
workforce that innovates in the manufacturing context through 
an iterative process that takes time to reconstitute, it can't 
happen all at once----
 Mr. Warner. Correct.
 Senator Young [continuing]. So, we're going to have to have 
sustained policy support for this approach.
 Mr. Warner. Correct. And if I could just add, and I'll give 
you a quick example, we had a USDA loan guarantee for $25 
million. There were a lot of reasons. In 2 years, we couldn't 
convert that into actual money, and it was structural. The 
program was built 25 years ago, and think about our facilities, 
$120 million or $115 million. A $25 million loan is like 
getting a 20 percent loan on your house. It's just too small. 
They weren't envisioned to match--there's no program to match 
the infrastructure we all need, be it USDA, DOE, and that's 
what I think needs to be looked at. If we want to manufacture 
biotech in the U.S., what does that look like? And most of the 
programs we're looking at are 30 years old. They weren't 
designed for the technologies we're trying to commercialize.
 Senator Young. I agree. You put it very well in your 
written testimony as well. So, this question will be directed 
at the entire panel, starting with Dr. Alexeenko and moving 
down the line. What are the biggest regulatory bottlenecks your 
company has faced in moving from discovery to clinical 
development, and how can Congress help streamline that pathway 
for other small firms? Try and be very brief here, please.
 Dr. Alexeenko-Peroulis. Yeah. Actually, the regulatory 
barriers are probably the largest. We can innovate other 
things, but it's very important to produce safe and efficacious 
medicines both for human and animal health. And, basically, 
we're constantly being asked, have you--what will FDA think 
about this technology?
 And, interestingly, when--let's take FDA example. The 
innovation in manufacturing mostly happens when there is a new 
drug product or biologic product. And this, the newest advanced 
manufacturing technology designation, is the first pathway 
within FDA to approve manufacturing technologies rather than 
approving new medicines so that new manufacturing can be 
applied without the clinical trial burden of developing new 
medicines. It would be just focused on manufacturing. So, this 
is one of the biggest issues in biotech manufacturing is linked 
to biotech products----
 Senator Young. Yes.
 Dr. Alexeenko-Peroulis [continuing]. And the regulatory 
barrier to innovate in manufacturing is almost as high as 
innovating a new product, because either you have to attach to 
a new product, or you have to find at least three products that 
are existing, approved products that----
 Senator Young. And you feel like the biomanufacturing 
regulations could be streamlined, and be----
 Dr. Alexeenko-Peroulis. They can definitely be----
 Senator Young [continuing]. Made more forgiving?
 Dr. Alexeenko-Peroulis [continuing]. Streamlined----
 Senator Young. Okay.
 Dr. Alexeenko-Peroulis [continuing]. And very important, 
the regulatory costs are very high. The timelines are--you 
know, it's----
 Senator Young. Yes.
 Dr. Alexeenko-Peroulis [continuing]. The opportunity cost 
of using GMP equipment----
 Senator Young. Yes.
 Dr. Alexeenko-Peroulis [continuing]. To test the new 
technologies is very high.
 Senator Young. Okay. Mr. Schacht.
 Mr. Schacht. Yeah. So, I would say the regulatory agency I 
have the most experience with in this context is the USDA. 
There was not a regulatory path for the kind of technology that 
we're bringing forward, and I've actually been pleasantly 
surprised. And I think it's the case of having a reviewer who 
has a background in the technology is a much greater advantage 
than having a reviewer who doesn't have any experience with 
your technology, and not everybody who walks up to the agency 
can benefit from that kind of fit. We've been lucky in that 
regard.
 I think one other--and so what I'll talk about are things 
that make it work as opposed to barriers, because they have 
resolved some barriers. And so, better fit or greater spread of 
competency of reviewers across the emerging biotechnology space 
would be good. A second item is, our technology is a 
genetically engineered microorganism, and there needs to be 
adjudication of that as being safe for the environment, safe 
for humans, safe for animals. And the historical process for 
getting something like that approved is very lengthy and 
indeterminate. It's a black box. You submit to the Federal 
Register, there's a public comment period, and you wait for 
some sort of synthesis of that. And this could be months and 
even years.
 We benefited this year or last year because the USDA 
decided that they could use the Federal Register process at 
their discretion and make that determination internal to the 
agency, which facilitated our receipt of authorization of our 
technology to move into the environment testing. And so, those 
are the kinds of regulatory reforms that actually work and work 
well.
 Senator Young. So, was this a novel interpretation by the 
USDA?
 Mr. Schacht. I think it was a cumulative analysis that 
indicated that they very seldom get input from the public 
domain through that Federal Register process that resulted in 
any other perspective than the one they already took on the 
product. And they're much closer to the product concept 
directly, technically, and so, in essence, what they found is 
we were soliciting input from sources that weren't providing 
meaningful input relative to the determination of the risk 
assessment.
 Senator Young. Thank you. Mr. Small, anything else to add 
on this front, sir?
 Mr. Small. Well, I mean, mine is definitely focusing mostly 
on FDA for the human product development, and, yeah, I really 
liked--I wrote down the expertise point, too, because that is 
always something. There's always somebody in the review process 
that's junior, or maybe not quite--shouldn't have that job yet, 
reading highly technical, you know, NMR spectra that are 
misinterpreted, which we've had happen on multiple products 
that we develop.
 So, expertise is one, but the examples that actually--
internationally, Australia. We go to Australia sometimes for 
running first clinical trials because the standards are a 
little bit lower. They're not unsafe, but they're lower, and 
they give us an opportunity to test those.
 Senator Young. We've, of course, looked at China.
 Mr. Small. Yeah.
 Senator Young [continuing]. And for the public to know, we 
don't aim to adopt China's morals and ethics as it relates to 
this, but they're fast, as are the Australians. We've looked at 
the Australians in terms of identifying----
 Mr. Small. Yeah.
 Senator Young [continuing]. How we might----
 Mr. Small. I've been to both----
 Senator Young [continuing]. Incorporate improvements.
 Mr. Small [continuing]. Places and run clinical trials in 
both places. In the United States, we always prefer to be in 
the United States. And so, they have to have huge costs and 
time savings for us to justify being over there for sure.
 Senator Young. Thank you, sir. Mr. Warner.
 Mr. Warner. The only comment--on the manufacturing side, we 
actually--we don't make GMP, we're industrial. So, I would say 
actually we face very little regulatory burden. The best news 
is most of the programs the Federal Government delegates, 
Indiana's fully authorized on most of the programs. They 
understand manufacturing.
 Senator Young. Yeah.
 Mr. Warner. So, this is one where we're in good shape.
 Senator Young. Just don't make eye contact, you know. 
[Laughter.]
 So, the next question I was going to ask, I think it's been 
covered in various ways, but if any of you feel like you'd like 
to add something here. What unique advantages do small 
businesses really have to offer as it relates to our biotech 
ecosystem? I found very interesting, Mr. Small, your citation 
of 80 percent of the drugs that FDA has approved have come from 
startups or small enterprises. So, that alone is really 
compelling to me, but does anyone else want to put in a plug 
for small business?
 Mr. Schacht. Yeah. Having lived in both worlds--25 years at 
Lilly in R&D, and now 6 years at Elanco, and now 5 years as a 
biotech entrepreneur, I would say that the problem-solving 
capacity and agility of a small company is unrivaled. That 
doesn't mean it can't be emulated in large companies, and there 
are many large companies that are trying to sort of reinvent 
themselves to allow for that. But the structural overhead and 
the bureaucratic component to managing a large organization 
sometimes gets in the way of doing the next thing, the next 
smartest thing, the fastest. So, I think small companies can 
only operate that way, and that creates advantage provided they 
have the resources necessary to solve the problem that they're 
facing.
 Senator Young. Thank you. The last topic I'm going to ask 
if any of you have additional comments to make in response to 
is I'm just throwing out supply chain resiliency as something 
I'd like to foot stomp here today because it's been the focus 
of so much of my work. I explain to people if they want a short 
encapsulation of things my office is working on right now; 
chip, ships, rocks, genes, and sometimes I throw in quantum. 
Chips, semiconductors, rocks are critical minerals. Genes, 
biotech. Quantum self is explanatory. But if you don't have 
access to a certain number of the key inputs, then you're going 
to be vulnerable to disruption, and that's an economic and 
national security issue. So, any other comments as we think 
about this? I thought you might have----
 Mr. Warner. If I could----
 Senator Young [continuing]. One, Mr. Warner.
 Mr. Warner. The program we saw that we thought was one of 
the best for what we needed, there was a supply chain program 
that came out of COVID. It was specific to animal proteins and 
things for the meat industry, but it applied to us. The money 
ended up getting pulled because it was COVID-related and 
retracted, but we think that the whole--for the areas the U.S. 
struggles historically on supply chains, we think that's a very 
good match. And it's, to some degree--I won't say not sexy, not 
interesting--but it's what keeps manufacturing going. And we do 
think that general supply chain resiliency should be a key 
driver of a lot of these, and I think you'll find biotech can 
support a lot of that.
 Mr. Schacht. Here's another example in the food production 
environment. So, the majority of vitamins as micronutrients for 
animal feed, for animal protein production, come from China. 
And the manufacturing base has moved over the decades to China, 
and its large synthetic manufacturing. I think there's an 
opportunity here in the U.S. to reshore vitamin B12 production, 
and other essential vitamins and nutrients that are critical to 
animal protein production, and do it in a way that's very 
resilient. You could imagine that if you lost those ingredients 
in U.S. agriculture, you would slow down U.S. production of 
animal protein, and I think that's a vulnerability.
 Dr. Alexeenko-Peroulis. This is a great question. Thank you 
so much. So, lyophilization is used as one of the kind of 
solutions to provide some supply chain resilience because it 
can be used to stockpile reagents, stockpile microorganisms, 
and store them for years and years and use them as needed, ship 
them, and so on. But, specifically, innovation in 
manufacturing, whatever it is, comes down at some point to, 
like, gallium nitride components. So, access even to materials 
is important, right, to printed circuit boards.
 So, we looked at our supply chain for LyoWave and we work 
very hard to get some resilience in that. And so, it's very 
much connected to semiconductor manufacturing, to access to 
even machining that's kind of somewhat flexible. Stainless 
steel, a lot of GMP equipment is stainless steel and machining 
stainless steel components. So, it is really all connected, and 
this--I think the large scale it needs to be addressed not by 
parts, and I think a lot of it has already been started with 
CHIPS and Science Act. But yeah, it's extremely, extremely--we 
can't make the--if we don't have the nails, we can lose the 
whole battle.
 Senator Young. Yeah. Well, one of the exciting things about 
solving this problem is that it can provide some good paying 
jobs. It's a happy byproduct of our efforts to become more 
resilient, right, and especially for a State that's strong in 
biotech and the most manufacturing-intensive State in the 
country. So, all kinds of opportunity. I thank our witnesses 
very much for your testimony here today. This concludes panel 
1, and we will take a short recess to switch panels, and we'll 
bring panel 2 forward shortly. So, thanks again to our 
witnesses on panel 1 for your time and testimony this morning.
 We're in recess.
 [Recess.]
 Senator Young. Thank you. You've been called to order. 
We'll now proceed to our second panel. Our first witness is Mr. 
David Rosenberg, president and CEO of Indiana University Launch 
Accelerator for Biosciences. For the uninitiated, that is IU 
LAB.
 Mr. Rosenberg. Yes.
 Senator Young. Prior to this role, Mr. Rosenberg served as 
Indiana's Secretary of Commerce, and he was previously the COO 
and chief of staff for the Indiana Economic Development 
Corporation. Mr. Rosenberg holds both a bachelor's degree and a 
J.D. from the Indiana University Bloomington.
 Next, Mr. Vince Wong is the president and CEO of 
BioCrossroads and Crossroads Health Ventures. He's also on the 
board of directors of the Indiana Biosciences Research 
Institute. He holds a bachelor's degree from the University of 
Notre Dame, and an MBA from Northwestern University. Our third 
witness is Michelle Dennis, regional innovation officer for 
Heartland BioWorks. Ms. Dennis also serves as vice president of 
regional life sciences programs at ARI, Applied Research 
Institute. She has a bachelor's degree from Indiana University 
Bloomington, and a master's degree from University College 
Dublin.
 I ask unanimous consent that the witnesses' full statements 
be included in the record. Without objection, so ordered. As 
your written testimony has been made part of the record, the 
committee asks that you limit your oral remarks to 5 minutes. 
And with that, Mr. Rosenberg, you're now recognized for 5 
minutes for your testimony.

 STATEMENT OF MR. DAVID ROSENBERG, PRESIDENT AND CEO, INDIANA 
 UNIVERSITY LAUNCH ACCELERATOR FOR BIOSCIENCES (IU LAB), 
 INDIANAPOLIS, INDIANA

 Mr. Rosenberg. Thank you, Senator Young, and distinguished 
guests. My name is David Rosenberg, the inaugural president and 
CEO of the Indiana University Launch Accelerator for 
Biosciences, better known as IU LAB. And yes, for the record, I 
do work for IU, the reigning college football champions. Again, 
that was just for the congressional record. [Laughter.]
 Senator Young. I've heard that.
 Mr. Rosenberg. Thank you for this hearing and for holding 
it here in Indiana. Where you hold a hearing like this matters. 
It signals something important that America's bioeconomy won't 
be built by a handful of coastal hubs alone. It will be built 
by States like Indiana and by the small businesses doing the 
hard work every day. Before this role, I served as Indiana 
Secretary of Commerce for 17 months. I saw firsthand what 
happens when a State decides to compete for the industries that 
will define the next generation of American strength, the 
industries of the future.
 In 2024 alone, Indiana closed with more than $39 billion of 
committed capital investment, helped launch a record 482 new 
businesses, and Indiana ranked as the most active venture 
capital investor in the Great Lakes region. What was clear 
then, and even more so now in my current role, is that life 
sciences isn't just an economic sector, but it is a strategic 
national security asset, and the small businesses driving this 
work will be how America competes, and it will be the only way 
the United States can truly win. That leadership will come from 
innovation, and more importantly, from the ability to start 
small businesses and scale them right here at home, in our 
universities, and with our ecosystem partners like those 
joining me today.
 Indiana is where the next generation of therapeutics, 
diagnostics devices, and biomanufacturing tools will be built 
right now. Indiana's life science sector represents $102 
billion annual footprint, 70,000 workers, average wages of 
$177,000. We are the radiopharmaceutical capital of the world 
and the reigning orthopedics capital of the world.
 IU LAB is our mission to further strengthen the State's 
economy and solidify America's global leadership. IU LAB was 
launched in 2024 with $138 million Lilly Endowment grant, and 
was part of IU's own $250 million life sciences investment. IU 
LAB is a first of its kind academic industry initiative, 
designed to shorten the distance between a discovery and a 
university lab, and a product that reaches a patient, a 
soldier, or a market, all while training the life science and 
biotech leaders of the future.
 Even before our permanent facility opens, the model is 
working. We signed a $40 million agreement with Eli Lilly, IU's 
largest industry-sponsored research agreement in history, to 
expand clinical trial and clinical care access for Hoosiers, 
and to advance Alzheimer's research. We signed a 5-year 
agreement with Cook Medical, and Cook already named IU as one 
of its first Interventional MRI Centers of Excellence, making 
surgical procedures safer and less invasive for patients.
 And this year alone, we're supporting 34 early-stage human 
health companies through our incubator program, companies like 
Osseo Labs, Amplified Sciences, and Qwyn AI, tackling 
everything from orthopedic surgery, to cancer detection, to 
drug manufacturing. They are here because our State has built 
an ecosystem that supports them, and they can be the next 
generation of companies that deliver America's innovation and 
economic security.
 IU LAB is also working to train the life science and 
biotech leaders of the future. We are building scalable 
pathways into bioscience careers, including new degree 
programs, industry-aligned curricula, and apprenticeship 
models. Through statewide partnerships, we're embedding 
education directly into innovation ecosystems so that students 
graduate ready to contribute on day one. And the demand is 
clear, between 2022 and 2024, life science wages in Indiana 
grew by 61 percent. The sector is expanding faster than we can 
staff it. Deploying a highly skilled and trained workforce will 
be the critical element for our nation's success.
 And last, IU has taken the National Security Commission on 
Emerging Biotechnologies work seriously, and we greatly 
appreciate your work, Senator Young, leading that Commission. 
We've already launched eight challenge grants aligned to the 
national priorities from AI-driven disease modeling to 
sustainable biomanufacturing, and to fully compete, we need 
even more Federal leadership and partnership opportunities.
 Based on what I've experienced firsthand and I've heard 
from small businesses, both during my time as secretary of 
commerce and now with the IU LAB, America is leading the race, 
but there is much more we can still do together for innovators 
now and all future generations. Thank you.
 [The prepared statement of Mr. Rosenberg follows.]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Senator Young. Mr. Wong, you're recognized for 5 minutes 
for your testimony.

STATEMENT OF MR. VINCENT WONG, CEO AND PRESIDENT, BIOCROSSROADS 
 AND CROSSROADS HEALTH VENTURES, INDIANAPOLIS, INDIANA

 Mr. Wong. Thank you, Senator Young, distinguished guests. 
My name is Vince Wong. I've served as CEO and president of 
BioCrossroads and Crossroads Health Ventures, and BioCrossroads 
is the statewide industry organization to advance life sciences 
here in Indiana. Thank you for the opportunity to testify on 
the efforts in Indiana to create the foundation for the 
formation of startups to support Indiana's--America's 
bioeconomy.
 In response to the clarion call to accelerate reshoring of 
biomanufacturing issued through your leadership of the National 
Security Commission on Emerging Biotechnology, Catalyze Indiana 
is an initiative that aims to position Indiana as the default 
destination for the invention, development, and implementation 
of next-generation technologies to enable the reshoring and 
manufacturing of the supply chain for medicines and food.
 Building on Indiana's unique strengths, including global 
industry leaders like Eli Lilly, Corteva, Elanco Animal Health, 
and world-class research universities, including Indiana 
University, Purdue University, University of Notre Dame, and 
Rural Hulman Institute of Technology, and the Nation's highest 
concentration of manufacturing jobs, as alluded to earlier, 
this initiative addresses critical gaps in domestic supply 
chain resilience for food and medicine production.
 Supported by a $69.4 million grant from Lilly Endowment and 
matching commitments from participating universities, the 
Catalyst Scholars Fund, spearheaded by Central Indiana 
Corporate Partnership, empowered by its branded initiatives, 
BioCrossroads and AgriNovus Indiana, will enable these Indiana 
higher education institutes to recruit 25 to 40 world-class 
faculty and their respective teams over 5 years, to tackle 
industry informed grand challenges in key platform technology 
areas including automation, analytical chemistry, new 
macromolecular technologies, waste separation technologies, AI, 
and computational medicines.
 Because we know that we cannot simply copy and paste the 
processes and operations that are presently in China and India 
to the United States. Because of economic and environmental 
sustainability reasons, we need to be investing in new platform 
technologies to enable that reshoring to happen. If 
successfully implemented, this Catalyze Indiana initiative will 
position Indiana at the forefront of national efforts to bring 
advanced chemistry manufacturing back to the United States to 
secure our supply of food and medicine.
 This catalytic investment will establish Indiana as a top 
destination for research and workforce talent, a magnet for 
industry manufacturing investments, and an engine for 
innovation in horizontal production platform technologies to 
ensure American leadership in advanced chemistry manufacturing 
across a wide range of sectors. It is the full expectation that 
many of the faculty recruited through the Catalyst Scholars 
Fund will serve as scientific and technical founders of 
startups that will further develop and ultimately commercialize 
the scholars, technologies, and inventions to ensure that their 
research has real-world impact. BioCrossroads, amongst the 
spectrum of partners in Indiana's innovation ecosystem, have 
developed and delivered a portfolio of programming and 
initiatives to inspire and support startup founders in their 
respective journeys to develop and commercialize impactful 
technologies and inventions.
 However, a critical gap that continues to persist is the 
lack of venture capital funding for bioscience startups in 
regions such as Indiana. Despite having promising discovery and 
inventions born in Indiana, the overwhelming concentration of 
necessary capital to fuel their development and growth is found 
in just three States; Massachusetts, California, and New York. 
The Federal Government can play a role to facilitate the 
broader dispersion and increase access of venture capital to 
communities such as Indiana, which are hotbeds for innovation 
vital to the national economy and national security. Thank you.
 [The prepared statement of Mr. Wong follows.]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Senator Young. Thank you, Mr. Wong. Ms. Dennis, you're 
recognized for 5 minutes.

STATEMENT OF MS. MICHELLE DENNIS, REGIONAL INNOVATION OFFICER, 
 HEARTLAND BIOWORKS, INDIANAPOLIS, INDIANA

 Ms. Dennis. Senator Young, and distinguished guests, thank 
you for the opportunity to provide this testimony.
 As regional innovation officer, I lead the heartland 
BioWorks Tech Hub, designated and funded by the U.S. Department 
of Commerce through the CHIPS and Science Act. With a focus on 
Indiana, the BioWorks mission is to support and grow our 
biotech and biomanufacturing sector. With that, I deal directly 
with the host of biotech and biomanufacturing companies from 
startups, including those that presented at the first panel, to 
the global leaders that we have here at the State as well.
 Startups and small businesses are the primary engines of 
innovation in biotech, often pioneering breakthrough therapies, 
diagnostics, and platforms that larger entities are slower to 
pursue. But addressing the challenges and opportunities 
specific to biotech innovation that were described by you, 
Senator Young, in your opening remarks as well as during the 
first panel, it takes an all-hands approach, and places like 
California and Massachusetts have shown that this works, but we 
need more of it. This is where Federal support and programs 
like the Tech Hubs and BioWorks come in.
 For years, Indiana has been bootstrapping its biotech 
innovation network in a determined attempt to smooth the 
pathway to startup success for its innovators. Now, through 
BioWorks coordination and EDA funding, we are overcoming long-
standing biotech innovation hurdles while growing our State's 
biomanufacturing sector. Heartland BioWorks was proud to 
represent the Hoosier State at the National Security Commission 
on Emerging Biotechnology's Biotech Across America State 
Symposium recently, and the message was clear: the future of 
biomanufacturing isn't just on the coasts.
 BioWorks coordinates the region's strong contract 
development and manufacturing organization, capacities and 
capabilities, and our robust pilot scale lab infrastructure, 
and funnels U.S. innovators to these resources by driving 
connections to existing, largely untapped Indiana 
commercialization resources. We help secure and accelerate 
domestic biotech startup success. We also award grants to both 
in-state and out-of-state biotech innovators developing new 
therapeutics and biomanufacturing innovations. These companies 
will now scale up in Indiana because of BioWorks and the EDA 
support that we have.
 These awardees are gaining access to state-of-the-art 
infrastructure, technical expertise, and startup mentorship 
that helps accelerate commercialization timelines, reduce 
costs, and mitigate risk, at the same time, connecting early-
stage startups with our scale up resources creates a business 
pipeline for these small- to mid-sized operations. It also 
enables CDMOs to engage with the latest biotech coming down the 
pipeline, allowing them to ensure their manufacturing processes 
are capable of keeping up with innovation.
 Through our coordinated approach, this infusion of Federal 
dollars is enabling BioWorks to achieve our aggressive goal: 
biotech invented in the U.S. is made in the U.S. Admittedly, we 
do not address all barriers to biotech startup success. The 
capital requirements are still overwhelmingly large. However, 
VC follows where there are proven nexuses of activity. By 
creating a legitimate innovation ecosystem in the Midwest, 
Indiana will no longer be a flyover State for investors.
 This still leaves regulatory challenges. However, this is 
an ideal opportunity for further Federal partnership. This 
isn't just a case of U.S. or other regions needing more VC 
activity. It's a case of multiple stakeholders rallying to make 
the biotech commercialization process faster, cheaper, and thus 
more attractive to investment.
 Complementary efforts by other critical Indiana life 
sciences entities, who are testifying with me today, are 
demonstrating that progress builds on momentum. Capitalizing on 
all of our work, Governor Brown recently announced an 
unprecedented $1 billion investment in Indiana's life sciences 
sector over the next 10 years. BioWorks through our many 
partners across Indiana is creating a replicable model of 
foundation setting that will enable biotech innovations to get 
out of the lab and turn into the small businesses we need. 
Through continued Federal support, partnership, and alignment, 
groundbreaking discoveries can be translated into new 
companies, high quality jobs, and globally competitive 
industries rooted in communities across the country.
 Recognizing the potential for Federal partnership, there 
are already grassroots efforts underway. BioWorks is leading a 
working group of biotechnology-related EDA Tech Hubs to share 
data, best practices, and exemplary programs. These regional 
hubs are located in the Midwest or other burgeoning regions, 
and thus share similar innovation, challenges, and 
opportunities. Leveraging the power of our Federal programs, we 
are working together to support our community's biotech 
startups and industry, and collectively maximize the impact of 
our programs. With further Federal support, we can do so much 
more, driving the Nation's global dominance in biotechnology.
 [The prepared statement of Ms. Dennis follows.]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Senator Young. Thank you, Ms. Dennis, and I thank all of 
our witnesses for their testimony. I'm going to begin with a 
definitional question, Mr. Wong, in the event it comes up 
again. Distinguish for me, chemistry and advanced chemistry 
manufacturing, something which is, oftentimes, emphasized as an 
area of emphasis for our State and biotechnology. Are they 
synonymous? Is chemistry a larger category----
 Mr. Wong. Yeah.
 Senator Young [continuing]. Or some other option?
 Mr. Wong. Sure. Thank you for the question. So, yes, 
chemistry would be a broader definition for biotechnology. 
Biotechnology is often synonymous with large molecule 
manufacturing, peptide manufacturing, vaccine manufacturing, 
typically administered through injectable means. Chemistry is a 
more broader foundational dimension that really crosses with 
small molecule cell gene therapy and large molecule 
manufacturing. So, it's really a foundational technology that 
really crosscuts through all kind of modalities of therapies, 
whether it be for animal, or plants, or humans.
 Senator Young. Okay. It's a sort of statement that Indiana 
wants to not only lead in biotech, but lead in this broader 
category. Is that accurate?
 Mr. Wong. That's correct.
 Senator Young. Mr. Rosenberg, we're done with definitions, 
at least for the time being. But through your work at IU LAB, 
you've seen firsthand how our State's life sciences ecosystem 
can help small businesses in the biotech industry. So, in your 
view and informed by this experience, how can universities 
better translate federally-funded research into successful 
startups?
 Because I have to tell you, as much as I make the broader 
conceptual argument for research, and I do this relentlessly, 
even when it's really unpopular, folks back home, they want to 
know that these investments are going to turn into businesses, 
and amazing products, and all the rest. And as part of your 
answer, maybe you can touch on any gaps that you think still 
exist and in moving innovations from the lab into the 
marketplace.
 Mr. Rosenberg. No, thank you for the question, Senator 
Young. I think there's two things. One, it's building the 
culture within the university. Thanks to the direction from 
President Whitten and the board, IU has really focused on how 
do we take IU's over $1 billion research enterprise and 
translate that into new inventions, commercialization, industry 
partnerships.
 IU LAB is intended to be the front door between our 
researchers and faculty, and those industry partners and 
startups that we can work with. I think it's building the 
scaffolding, the programming internally, to show a researcher 
who's done research their entire life that there is this second 
act of translating their research and moving it forward. But it 
does take the entire enterprise. One of our goals is how can we 
get a researcher in school of medicine partnered with someone 
from Kelley School of Business or Luddy School of Informatics 
to take that idea and turn it into a business plan, and to 
adopt AI into it to really grow it. And so, I think the 
university, again, thanks to President Whitten's direction, is 
really focused on building that culture, creating those 
pathways for researchers to become entrepreneurs and be able to 
grow that.
 I think the second is stepping off of the university campus 
and engaging with the ecosystem. We have incredible partners up 
here today that we work with very closely. IU health has 
sponsored our IU health incubator, IU LAB, which includes a 
pre-accelerator which is managed by generator, and then our 
LifeTech Accelerator, which is managed by Plug and Play and 
BioCrossroads. It's a unique, first-of-its-kind program that 
brings the expertise of these different groups that have 
international networks and reach together so that we can be the 
human health hub to bring those companies here, to develop them 
and work with our partners.
 In terms of the gap, I think Vince, Mr. Wong, mentioned it 
well, in terms of venture funding, I think venture finds good 
ideas, but there's more we can do to further attract them and 
bring them into the State. I also think in terms of graduation 
space for startups, whether it's IBRI or our IU Health's ICB, 
there's that early-stage lab space. We could always use more, 
but there are options. It's that company that's, you know, 5 to 
10 employees looking to make their next step out of kind of the 
innovation lab into graduation space that we could use a lot 
more of, especially around central Indiana to keep more of 
those companies here and not let them leave the State.
 Senator Young. Thank you for that comprehensive response. A 
couple of reflections I have based on your response. Number 
one, I as much as important, and this was the predicate for my 
question, as important as being able to articulate to our 
stakeholders, our constituents, the value proposition of jobs 
and products is they also want to know that the way we 
administratively are investing these dollars is as smart as 
possible. And I think artificial intelligence is going to--from 
everything I hear, it's going to make us far more efficient in 
the research lab, among other areas.
 And I think it's important that we communicate to our 
constituents how much more efficient we're becoming in 
discovering new, lifesaving, life-improving products, and 
that's going to be very important moving forward. I had another 
point, but I've lost it. I'll capture it again later, but Mr. 
Wong, I will move on to you in the meanwhile. From a regional 
innovation perspective, what distinguishes successful biotech 
hubs, and what Federal policies could help replicate, what I 
will without a measure of humility call, Indiana's model across 
other parts of the country? Not we should be trying to follow 
Boston, or San Diego, or San Francisco, or Austin, but others 
should be looking to replicate what we're doing. I would 
welcome their efforts. What advice would you give them?
 Mr. Wong. Yeah, I think, what's distinctive about our 
ecosystem, Senator Young, that should be compelling to 
startups. You know, when an asset is coming out of a lab and 
ultimately is protected through IP, there is a shelf life from 
an intellectual property protection perspective. So, every day 
that that asset is not getting to patients means revenue loss 
potential and then also loss potential impact for patients. And 
so, the ability to move fast, for companies to be able to move 
fast through the entire value chain, I think is really 
important.
 And I think what Indiana has is quite a unique value 
proposition in that respect. There's certainly very strong 
invention happening here. And, Derek, and Aaron spoke about 
that earlier in the prior panel about some of the great 
invention happening here, but also, Indiana also has great 
manufacturing and also supply chain as well. So, to have a 
fully integrated value chain here within central Indiana, gives 
us, I think, competitive advantage for companies that want to 
move fast and move assets through the entire value chain 
quickly.
 I think also what distinguishes our ecosystem from others 
like Boston and San Diego, is we are highly collaborative. I 
think, you know, all three of our organizations, and----
 Senator Young. Which is related to your previous point, 
right?
 Mr. Wong [continuing]. That also enables----
 Senator Young. If you want every spot along the value chain 
to be on a real-time basis to be buttoned up. It takes constant 
collaboration. Is that accurate?
 Mr. Wong. That's right, I think there's the level of 
collaboration between universities and industry, between 
philanthropy, and government, and industry. It's, you know--
I've got exposure to other ecosystems, won't name them, but, 
they're quite dysfunctional, I would say. And they struggle to 
be able to get off the dime and work together. And I think I 
feel very fortunate to be working in a collaborative 
environment that is Indiana in that respect.
 Senator Young. Could you name those other ecosystems----
 [Laughter.]
 Mr. Wong? They'll remain anonymous. All right. I tried.
 Ms. Dennis, turning to you, how can public-private 
partnerships and Federal investments be designed to strengthen 
domestic biomanufacturing capacity, something we're focused on 
real time. You're focused on real time at Heartland and thereby 
reduce U.S. reliance on foreign supply chains.
 Ms. Dennis. I think it's through two approaches. I think 
that we would first value or benefit from Federal coordination 
of just inventorying what we have, and where it is, and where 
the strengths are, the key capabilities are. And then from 
that, using that to develop a very coordinated and strategic 
investment policy that helps bridge the valley of gap that Mr. 
Warner mentioned earlier today.
 We have a lot of investment that's happening in 
biomanufacturing with Eli Lilly across the country, and that's 
a phenomenal to see. But we also need those types of facilities 
that others can access as well, particularly the small 
businesses. And so, that takes a lot of coordination and very 
targeted investment. And right now, there is just a gap in the 
ability to secure funds to do that, to be able to have 
companies scaling up here in the states.
 And so, I think it's first just identifying where are the 
specific gaps? How can we all work together to make sure that 
we're using all the resources we have? And then, how can we 
fill those gaps to make sure that we can do everything here 
domestically and keep companies here?
 Senator Young. And so, I'll ask you for a little more 
precision about the type of infrastructure we need to invest 
in. Is this infrastructure to serve the small group of 
entrepreneurs, or the single entrepreneur that has a great idea 
and they want to ultimately turn this into a product, and they 
need a shared infrastructure, they can visit and develop that 
idea further, or are you referring to other types of 
infrastructure?
 Ms. Dennis. I think it's one scale higher than that. The 
shared infrastructure, just to test out directly out of the lab 
largely exists in Indiana and across the country. It's fairly 
untapped, and it's not well inventoried, again, but that 
exists. I think it's getting to that next scale before you're 
making these bigger batches of product to where--that's where 
it's a challenge is to get those intermediary scales, and 
that's when companies are going overseas because it's 
available. Companies are willing to take these small batches 
and scale them up there and provide a lot of support. And so, 
then, as Mr. Warner described, then everything goes over there. 
But it's that in between scale that that we just don't have a 
lot of opportunity for the business model is hard for it for a 
private firm to take that on.
 Senator Young. So, unpack for me and members of the public 
how this works. As you're headed into that next stage where you 
require some scaling infrastructure and presumably expertise is 
the innovator who already has developed their concept to that 
point. Figure it out. They have something which, if they were 
able to produce it at scale, could become a very useful product 
to others. Is it accurate that they require not only the 
infrastructure, but, a fairly high level of biomanufacturing 
expertise?
 Which the reason I ask this is if you saw my interaction 
with Mr. Warner earlier, this is something that he and I sort 
of went back, and forth, and emphasized. It's not just the hard 
infrastructure. It's hard to manufacture at scale and with 
fidelity, living things, new living things. So, if anyone--Ms. 
Dennis and then if anyone else wants to speak to this.
 Ms. Dennis. Yeah, the expertise is critical. So, when 
you're taking your product into a manufacturing environment to 
have them produce it for you, it's a very integrated 
partnership to where they're using their scientists and 
engineers to help formulate and scale the product with you 
collaboratively. That takes a lot of resources. And so, at the 
moment when companies do go overseas to do that, they're being 
handed free post-docs and free expertise, essentially, to help 
them do that and guide them through that process. That model is 
hard to replicate over here. And so, it's both--it's not just 
having the bioreactors that have capacity that you can use. 
It's having that expertise as well, and so there's a lot to it.
 Mr. Wong. Yeah, I would reiterate what Ms. Dennis shared. 
And I think it's--you know, Eli Lilly, I think is kind of 
vertically integrating themselves. I think they were tired of 
trying to wait for capacity amongst their contract 
manufacturing partners for that early in-human study material. 
And so, they are investing for themselves to develop that 
capability up in Lebanon at the LEAP District.
 But there are a lot of other companies that don't have that 
capability to kind of vertically integrate that capability 
within their four walls of their organization, so to speak to, 
you know, really speaks to the need that Ms. Dennis is 
referring to is that first in human dose of trial material? 
It's hard to get existing CDMOs to pay attention to those 
smaller batches because they've got such demand coming from 
bigger customers and bigger batches. That makes it kind of for 
them and financial unattractive to divert their capacity for 
these smaller production levels.
 Senator Young. Let me zoom out and think about the national 
value proposition to developing this capacity, more of this 
capacity here in the United States, potentially in a State like 
Indiana. Supply chain resiliency, would that be one of the 
value propositions to avoid interruptions in supply chain? 
Quality control, is this another area? My discussions with Eli 
Lilly, I think that's--is that accurate, Mr. Wong?
 Mr. Wong. Yeah, certainly quality control is important, and 
then I think it was alluded to earlier by Mr. Warner, is just 
the process development capabilities and technologies, that 
know how when to take things, you know, overseas, then you're 
inherently feeding into their flywheel of knowledge and 
innovation. Whereas, you know, if we can keep that innovation 
and know how here domestically, I think would serve as well.
 Senator Young. Which is the last area that I discern here, 
which is intellectual property to be more pointed about it. 
There's a risk if you're sending over a not fully developed 
product to another country that they reverse engineer the 
secret sauce and beat you to the market in certain areas. Is 
that accurate?
 Mr. Wong. That's accurate and is also intellectual 
property, whether it be patentable or not, just in terms of how 
the--really the process chemistry of how do you translate a 
molecule into a manufacturable product? And so, you know, that 
know how is very valuable and should be cultivated, and 
nurtured, and invested here domestically.
 Senator Young. Thank you. So, the remaining questions I'm 
going to have will be addressed to all of you on this next one. 
I'll start with Mr. Rosenberg and move down the line. And your 
view, Mr. Rosenberg, what's the single most important action 
Congress can take in the next year to ensure the United States 
remains the global leader in biotech innovation?
 Mr. Rosenberg. Yes. So, I think the first two were 
addressed well in the first panel. And that's sustain and 
expand SBIR and STTR these programs work, and we hear 
constantly from startups leaning into them. And the ROI can be 
tremendous. The second is the speed and clarity to the 
regulatory pathways, especially with the new AI-enabled medical 
technologies that are being developed on a daily basis.
 The third, I think, is investing in the university industry 
infrastructure, as we've seen at IU LAB. Thanks to your 
leadership with the National Security Commission on Emerging 
Biotechnology, IU has been a fast mover in that front, where we 
launched grants to eight multidisciplinary teams within the 
university to align with the national priorities that came out 
of your Commission. And so, we are ready when that funding 
moves forward to be able to act because we've done the pre-work 
and we want to be supportive of that.
 The second is, you know, with IU Inc., which was adopted by 
the IU Board of Trustees in February. It is a 501(c)(3) that 
will sit outside of the university to allow that nimbleness and 
new infrastructure and financial structures with companies to 
be able to go after Federal grants through a consortium, a 
university-industry consortium, more opportunities aligned with 
that to take innovation into the industry, and continue to 
evolve the innovation and commercialization opportunities, I 
think, would be very welcome.
 And then last, is continuing to build the workforce. The 
Federal investment in stackable credentials and industry-linked 
opportunities will be critical to retain that talent, not only 
in States like Indiana, but also the workforce for the United 
States.
 Senator Young. Thank you. Mr. Wong.
 Mr. Wong. I think additional support that the Federal 
Government could play, I think, was also alluded to in prior 
panels was really creation of facilities for pilot-scale 
demonstration of technology. I think, you know, there's really 
been discussion of two different phenotypes here. One is R&D 
for manufacturing, and then manufacturing for R&D. I think 
there's a need for both--investments in both areas. Catalyze 
Indiana is really focused on the R&D for manufacturing. And so, 
we want to develop beyond creating this investment fund to 
attract researchers to Indiana.
 We also want to develop a network of really proving grounds 
or sandboxes for the innovations that will come out from these 
researchers to be able to demonstrate those technologies before 
they go into a full GMP environment. And so, I think this is an 
area where, you know, the Federal and State government can also 
invest. We've already got commitments from philanthropy and 
industry to be investing in this initiative. I think having 
government support as well, to supercharge those efforts, would 
be highly beneficial.
 And then, you know, I think Dennis talked about this 
earlier as well, is just this the need for, you know, R&D, 
manufacturing for R&D, which is, you know, that capacity for 
smaller scale manufacturing for early-stage clinical study 
material. Again, that gets crowded out at the CDMO level and 
really makes startups go overseas to China or India to make 
that early clinical trial material. That should be, again, 
manufactured here domestically.
 Senator Young. Ms. Dennis, what comes to mind? What can 
Congress do in the next year to stay on top as it relates to 
biotech.
 Ms. Dennis. Yeah, I mean, I would support everything that 
has been mentioned. And then, in addition, there has been 
amazing investment in all of these regional hubs, and we're 
developing a lot of really great programs that are benefiting 
our regions. I think that the next step then is to say: what 
can we pull out of those, and then share, and have a real 
collaborative network, and then incentivize the use of those 
best practices?
 So, for example, we have all the bio-related tech hubs that 
are collaborating informally and helping to avoid redundancies 
so that we don't have to reinvent the wheel to develop 
workforce programs and in commercialization best practices. It 
would be great for that to be formalized at the Federal level 
to where these best practices are somewhat codified, and then 
regions are incentivized and supported to implement those best 
practices in their regions so that we can just accelerate 
progress much more quickly.
 Senator Young. We'd love to work with you and other 
stakeholders on that. And I should add, there's a real 
opportunity here for Farm Country USA, because what goes in 
these, oftentimes, steel tanks, to grow new products is 
agriculture feedstocks. So, we can take high value added. What 
currently would, oftentimes, be regarded as Ag waste products, 
put them in tanks, an extra stream of revenue for our farmers 
and then have high paid, high skilled biomanufacturing jobs 
across rural America. It's energy efficient to produce near 
where things are consumed.
 Think of all the value propositions in Indiana's well 
situated to kind of lead the way on a lot of this. I would ask, 
Mr. Rosenberg, indicated that among the things we really need 
to be focused on is workforce, of course, Indiana University 
doing as good a work as anyone to prepare our workforce to 
offer the sort of value we talked about today.
 But Mr. Wong, Ms. Dennis, as it relates to workforce, at 
what stage are experience levels--are there the most 
significant workforce gaps when it comes to biotech or 
chemistry, if you prefer? And what role should Federal policy 
play in building a stronger, more scalable biotech workforce 
pipeline?
 Mr. Wong. The approach that we're trying to take here in 
Indiana, Senator, is really focused on attacking it by kind of 
demographic-by-demographic group. We've got K-12 initiatives. 
We've got initiatives to target college graduates and then also 
working adults that are already in workforce, but maybe not in 
our industry. And so, we're trying to meet people where they 
are and create pathways for them to get meaningful and 
rewarding career pathways into our industry.
 On the K-12 side, and I'll let Ms. Dennis talk about kind 
of the college graduate efforts that her organization is 
leading, but on the K-12 side, really as a State, we're 
importing Swiss-based apprenticeships model that is also found 
in Germany, and Austria, and other Northern European countries 
to good effect and really give meaningful, experience-based, 
work-based learning experiences starting in sophomore, junior 
year in high school.
 I think we often undersell what high school students can do 
and learn at the workplace and the value of experiential 
learning. We're trying to change and fundamentally, really 
reinvent education in that respect. And so, we're creating 
apprenticeship programs starting in sophomore year. I focused 
initially on biomanufacturing jobs, and hope that that will 
inspire the next generation of people to really get rewarding 
occupations and pathways in our industry to really then support 
the growth that our industry has here in Indiana.
 Senator Young. I'll turn to Ms. Dennis, and then I'll go 
back to Mr. Rosenberg, because I know he did some important 
work in this space in his previous capacity.
 Ms. Dennis. So, yeah, the workforce piece is critical 
especially when you're looking at the manufacturing side of the 
pipeline. One of our biggest needs is really just lab techs and 
operators. So, those that are on the floor being able to make 
the product and that speaks to supply chain, and it speaks to 
the success of trying to get those investments happening here 
in the U.S. And so, in terms of the support that the Federal 
Government can play, obviously, it's funding.
 It takes a lot of work to be able to have facilities 
available to train workers, to get them out onto the floor as 
quickly as possible. But again, it's also that coordination 
that the Federal Government can help with as well. The amount 
of time that we have spent in BioCrossroads led most of this, 
of just trying to understand what skills and abilities 
companies needed for these workers so then we could develop 
curriculum that gave them those KSAs as quickly as possible to 
get them onto the floor.
 That took a lot of work, and I know all of our other sister 
regions are doing the exact same process reinventing that 
wheel, talking to their industries when the competencies are 
pretty much shared, and so, coordinating that type of data 
sharing. And those, again, types of best practices can help us 
develop a national workforce much more quickly, and I think 
Indiana has a very strong model that can be shareable and 
replicable that we're working to develop here.
 Senator Young. Can our statewide community college system, 
Ivy Tech Community College, be a force multiplier as it relates 
to some of the technician level jobs? Because I would imagine 
not all these jobs require a bachelor's degree, certainly not a 
post-doctorate degree?
 Ms. Dennis. Absolutely. So, they are a key partner that we 
work with.
 Senator Young. What we call a leading question in the 
business.
 Ms. Dennis. Yes, and especially because they are statewide. 
We're very lucky that we have a statewide system so that you 
can rapidly expand programs. And so, most of these positions 
don't even really require certificate. We're developing 
curriculum in partnership with Purdue and Ivy Tech. That is 6 
to 8 weeks, and then people are on the floor. And so, those 
educational partners are key to be able to get those deployed 
quickly.
 Senator Young. It's fantastic. And as far as I understand 
it, Purdue and Ivy Tech have partnered, as has IU, Ivy 
partnered with the local Ivy Tech branch in some different 
discrete areas. Mr. Rosenberg.
 Mr. Rosenberg. Thank you, Senator Young. With my previous 
status as secretary of commerce, you know, the university is 
doing an incredible job of bringing in talent. I think, you 
know, per capita during the school year, Indiana has some of 
the most--you know, one of the highest per capita of knowledge 
and learners in the entire country thanks to our university 
system. Our goal at the State was really: how do we keep them 
here?
 And we do that by two ways is having those interesting 
industries of the future and jobs, not only jobs, but careers 
that those, you know, learners could see themselves in long-
term. And how do we create that stickiness at an early age so 
that when they graduate, they already have the connections in 
the industry and they want to plant their flag here. And then, 
second, is how do we develop the communities in which they want 
to live? So, many graduates now go to a place where they want 
to live and find a job there, instead of--you know, 
historically it was find a job and that's where you live.
 And so, we need to create the community, the environment, 
the built ecosystem for where those learners want to live at IU 
currently. You know, we're doing that in a couple of ways, but 
one of those big ways is leaning into artificial intelligence. 
So, many of the startups that we see coming through our 
incubator now are in that AI space, whether from drug discovery 
or genome sequencing sensors, quality control, or organoids on 
a chip, which I cannot expand upon beyond that.
 But IU has launched its Gen AI 101 and Gen AI 201 courses. 
It's open to all IU students, faculty, alumni, and now, we're 
piloting it with Indiana businesses. That baseline knowledge of 
artificial intelligence and how you use it on a day-to-day 
basis is no longer optional. It's a requirement for so many 
businesses that are leaning in that way. We've had over 120,000 
students, faculty, and alumni enroll in that, and we'll 
continue to grow that in partnership with our industry 
partners, again, so that when students graduate, they have 
those connections and they can contribute to those businesses 
on day one.
 Senator Young. That's fantastic. That's fantastic. And that 
in my observation experience, that's the handoff from your 
universities to the labor market has been an area that has 
required a lot of work. And I know that President Whitten is 
really emphasizing the importance of that.
 So, one more question for the full panel today. As small 
biotech companies grow, many face challenges navigating 
partnerships with larger firms, investors, and Federal 
agencies. What can be done to ensure--and we'll start with Ms. 
Dennis--what can be done to ensure that small businesses are 
able to compete fairly, retain their innovations, and 
successfully scale without being crowded out?
 Ms. Dennis. I think it's important that they receive the 
support that they need to be able to do that. It is 
complicated, and most of the startups, these are their 
technical experts. And so, the programs that BioCrossroads and 
IU LAB are implementing, and that we're helping to support to 
be able to create, basically, wraparound services around these 
companies to help them rapidly get through the regulatory 
environment, to help them have conversations with investors 
that are actually successful so that they're not having to do 
everything on their own while also being experts in the 
science.
 And again, I think it speaks to the collaborative nature 
that we have here in Indiana to where there could be one 
company that all three of our organizations are working to help 
support, and we all play a piece in that, and I think that 
that's critical to helping get them out of that space and be 
able to be successful.
 Senator Young. Thank you. Mr. Wong.
 Mr. Wong. Maybe I'll pivot to, you know, wearing my hat as 
an investor at the seed stage, but also my prior experience 
helping lead a startup developing cancer prevention platform 
leveraging RNA technology. I think it was alluded to in prior, 
panel, just talking about all the number of regulatory 
agencies. So, if--you know, I think it's great to develop a 
therapy, but also if you develop something that helps prevent a 
disease like a cancer screening test, for example, you not only 
have to deal with the FDA, you also have to deal with the CMS, 
the Medicare and Medicaid services.
 But then, even after you get FDA approval, even after you 
get coverage from CMS, you will not get covered by private 
insurance unless you've been really put on that good 
housekeeping seal of approval by the U.S. Preventive Services 
Task Force, USPSTF, which is a small little agency under HHS. 
Unfortunately, USPSTF only reviews as a category every 6 to 7 
years. So, technology advances much faster than 6 or 7 years. 
And so, if you're on the outside of that review cycle, you 
could be sitting on the sideline.
 Senator Young. Well, I'm going to stop you right there----
 Mr. Wong. Yeah.
 Senator Young [continuing]. Not because it's unimportant, 
but because it's important. Should that be once every 5 years? 
Should it be twice a year, or is there a reason why they have 
once every 6 or 7 years?
 Mr. Wong. I think largely it's a function of the fact that 
the panel members on USPSTF review board are volunteers, and so 
they only have a certain finite capacity to review all the 
different categories. I think they've got 40 categories of 
different preventative types of products that they review, and 
so it's just like a cycle.
 Senator Young. Should they be----
 Mr. Wong. Should be every 3 years, I think.
 Senator Young. Should they be--oh, it should be once every 
few years.
 Mr. Wong. Every 3 years, I would say.
 Senator Young. Okay. I wouldn't expect you to know the 
answer to this, but could this be solved through asking more 
people to volunteer?
 Mr. Wong. It could be expansion of the panel and create 
subspecialties of the panel. Right now, it's one large panel 
reviewing all categories without subcommittees.
 Senator Young. Is it possible in this age of AI that we 
could make volunteering less painful and more efficient?
 Mr. Wong. Absolutely. I mean, I would suggest that if a 
product has been FDA-approved, if a product has gotten CMS 
coverage, that there shouldn't be an additional approval by 
USPSTF. The USPSTF should give up their discretion if you've 
got FDA and CMS coverage, that that should give you USPSTF 
approval.
 Senator Young. Might we consider a shot clock? And if the 
proverbial ball is not released, that is decisions not made by 
us, then it's automatically approved?
 Mr. Wong. It definitely should have some kind of time 
limit. Right now, there is no time limit.
 Senator Young. But it sounded like what you were proposing 
could be a little more revolutionary. I won't repeat it lest it 
be quoted, but eliminating that final line of defense with 
USPSTF altogether as a possibility. I see Mr. Rosenberg is 
chomping at the bit. So, is that accurate, sir? Did you want to 
speak to this particular issue?
 Mr. Rosenberg. I'm going to try to be----
 Senator Young. Okay. It's like being in--all right, it's 
like you're at an auction. You raised your hand.
 Mr. Rosenberg. I want to be less revolutionary than Mr. 
Wong.
 Senator Young. Okay. Yes, please, Mr. Rosenberg. Thank you, 
Mr. Wong.
 Mr. Rosenberg. Yes. The advice for startups is engage in 
the ecosystem. That is the Hoosier secret sauce. Very few, if 
any, can do what we can do here in Central Indiana with the 
partners that we have, the mentorship that we have, 
universities being a partner, leaders like Crossroads and ARI, 
with Heartland BioWorks, largest medical school in the country 
and leadership across the board in manufacturing. So, there are 
very few other ecosystems, but the startups themselves have to 
lean in, get involved, figure out what the network is, and 
they'll find the help.
 Senator Young. Thank you. Mr. Wong, we can follow-up on 
that other matter because we're coming to the very end. And I 
want to thank our witnesses on the second panel, but also in 
the earlier panel for being here today. I want to thank all of 
the concerned citizens, members of the press and others. Of 
course, I want to thank staff. I want to thank our Small 
Business Committee staff that does a wonderful job in 
Washington, but really around the country, I think Senate staff 
is, oftentimes, not mentioned enough. I know all of you think 
that I'm a master of the universe. I do all this by myself, but 
I get a great deal of assistance. And Lucy Sadler here on my 
personal staff, I should mention her, our communications team. 
We have law enforcement here.
 All right. I've acknowledged, I think, everyone in the room 
except for the City of Carmel, and I want to thank the mayor 
for making this space available. I ask unanimous consent that 
the record of today's hearing remain open for 2 weeks for 
members to submit questions, revise, and extend their remarks 
and submit additional information into the record.
 Without objection, so ordered.
 With that, the Committee on Small Business and 
Entrepreneurship stands adjourned.
 [Whereupon, at 12:27 p.m., the hearing was adjourned.]

 [all]